SCHEMBL10249147

SCHEMBL10249147

CCOC(=O)c1cnccc1-c1nc2cc(C)cnc2n1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
HPGD P15428 3/20 0.41
MAPK1 P28482 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CLK1 P49759 1/20 0.41
UBE2N P61088 1/20 0.41
CSNK1D P48730 1/20 0.40
MMP13 P45452 1/20 0.39
NPC1 O15118 5/20 0.38
RAB9A P51151 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38
MAPT P10636 2/20 0.38
CDC7 O00311 2/20 0.38
DBF4 Q9UBU7 1/20 0.38
ROCK2 O75116 1/20 0.38
PIM1 P11309 1/20 0.38
GSK3B P49841 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249325 0.89 CYP46A1 (0.41) ALDH1A1HSD17B10SMN1; SMN2KDM4EGLA
SCHEMBL10284543 0.87 POLB (0.54) ALDH1A1HPGDMAPK1HSD17B10CLK1
SCHEMBL10249095 0.85 KDM4C (0.37) ALDH1A1SMN1; SMN2POLBPDE10A
SCHEMBL10252614 0.84 SIRT3 (0.47) SMN1; SMN2KDM4EPOLBMKNK1MKNK2
SCHEMBL10249120 0.84 PDE10A (0.36) ALDH1A1HPGDHSD17B10NPC1RAB9A
SCHEMBL10252639 0.84 PDE2A (0.39) HSD17B10SMN1; SMN2PIM1PDE10A
SCHEMBL10249139 0.82 PFKFB3 (0.36) ALDH1A1HPGDSMN1; SMN2MAPTKDM4E
SCHEMBL10249121 0.82 PFKFB3 (0.35) SMN1; SMN2POLBPDE10A
SCHEMBL10249245 0.81 POLB (0.35) ALDH1A1SMN1; SMN2POLBPDE10A
SCHEMBL10249089 0.81 POLB (0.40) SMN1; SMN2POLBLMNAPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 ALDH1A1 1409/4885HPGD 2801/4885MAPK1 1099/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 ALDH1A1 1409/4885HPGD 2801/4885MAPK1 1099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.